

## **Product datasheet for TL315033V**

#### OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## **ABCA8 Human shRNA Lentiviral Particle (Locus ID 10351)**

### **Product data:**

**Product Type:** shRNA Lentiviral Particles

**Product Name:** ABCA8 Human shRNA Lentiviral Particle (Locus ID 10351)

**Locus ID:** 10351

**Vector:** pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: ABCA8 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

**RefSeq:** NM 001288985, NM 001288986, NM 007168, NM 007168.1, NM 007168.2, NM 007168.3,

NM 001288986.1, NM 001288985.1, BC010392, BC024003, BC037309, BC047765, BC094689, BC130280, BC143971, BC143972, BM665457, BM707283, NM 007168.4, NM 001288985.2

**UniProt ID:** <u>094911</u>

**Summary:** The membrane-associated protein encoded by this gene is a member of the superfamily of

ATP-binding cassette (ABC) transporters. ABC proteins transport various molecules across extra- and intracellular membranes. ABC genes are divided into seven distinct subfamilies (ABC1, MDR/TAP, MRP, ALD, OABP, GCN20, White). This protein is a member of the ABC1 subfamily. Members of the ABC1 subfamily comprise the only major ABC subfamily found exclusively in multicellular eukaryotes. The encoded protein may regulate lipid metabolism and be involved in the formation and maintenance of myelin. Alternative splicing results in

multiple transcript variants. [provided by RefSeq, Jan 2014]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.







# Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).